

# Smallpox Vaccine Work Group Introduction

Lee Harrison, MD  
ACIP, Work Group Chair

February 27, 2014



# Background

- Numerous occurrences of laboratory-acquired vaccinia infection have been reported
- Smallpox vaccine provides cross-protection against all orthopoxviruses (smallpox, monkeypox, vaccinia, and cowpox)
- Smallpox vaccine used to protect clinical and research laboratory workers against these viruses



# Ocular vaccinia infection in laboratory worker treated with VIG and with full recovery




Primary lesion: Inner canthus



Satellite lesion: Lower conjunctiva

Lewis FMT et al. Emerg Infect Dis 2006;12:134

# Needlestick inoculation of vaccinia virus in laboratory worker



Moussatché N et al. *Emerg Infect Dis* 2003;9:724



# Left eye and right ear of man with laboratory-acquired vaccinia infection



# Background

- ACIP recommendations for smallpox vaccination of laboratory workers not updated since 2003
- New smallpox vaccine, ACAM2000, licensed in 2007 and has replaced previously used smallpox vaccine, Dryvax



# Background

- Smallpox Vaccine Work group established in March 2013
- Monthly meetings held since that time



# Work Group Members

## ACIP Members

Lee Harrison, Chair

Nana Bennett

## Liaisons

Greg Poland (ACP)

Grace Kubin (APHL)

Howard Minkoff (ACOG)

May Chu (CLIAC)

## FDA

Doran Fink

Sixun Yang

## DOD

Limone Collins

Jay Montgomery

## NIH

Mark Challberg

Richard Gorman

James Schmitt

## Consultants / Content Experts

Stuart Isaacs (University of PA)

Mike Merchlinsky (BARDA)

Richard Greenberg (University of KY)

Richard Moyer (University of FL)

## CDC

Brett Petersen (Designated Federal Official)

Mary Reynolds

Inger Damon

Shannon Keckler

Tiara Harms

Mike McNeil (ISO)

Maria Cano (ISO)

Jesse Geibe

Alison Mawle





# Terms of Reference

1. Review recommendations for smallpox vaccination for lab workers in 2001 statement (and supplements from 2003)
  - a. Review Biosafety in Microbiological and Biomedical Laboratories (BMBL) requirements for work with orthopoxviruses
  - b. Review orthopoxvirus laboratory exposure cases and reports



# Terms of Reference

2. Review data on smallpox vaccine:
  - a. ACAM2000
    - Safety and immunogenicity data
    - Adverse event rates with current stringent prescreening program
  - b. Dryvax: Publications on 2002–2004 pre-event smallpox vaccination program

# Terms of Reference

3. Review human safety and animal model efficacy data for attenuated smallpox vaccine IMVAMUNE stored in Strategic National Stockpile and potential role in smallpox vaccination for lab workers (unlicensed product and therefore informational)



# Terms of Reference

4. Review data on recombinant vaccinia viruses in development or under investigation in clinical trials to provide guidance on need for smallpox vaccination in healthcare and/or laboratory personnel working with these viruses



# Terms of Reference

5. Revise existing statement and supplements for smallpox vaccination of laboratory workers into single ACIP Policy Note document



# Thank you

